Global Particle Therapy Market to Reach USD 1,601.60 Million by 2032 | CAGR of 6.6%
Category : Healthcare | Published Date : Jan 2025 | Type : Press Release
Particle Therapy Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Particle Therapy Market was valued at USD 960.54 million in 2024 and is projected to grow at a CAGR of 6.6%, reaching USD 1,601.60 million by 2032. Particle therapy is an advanced form of radiation therapy that uses high-energy proton or carbon ion beams for targeted cancer treatment. This technology provides high precision in targeting tumors, minimizing damage to surrounding healthy tissues, and reducing side effects. It is particularly effective for treating pediatric cancers, deep-seated tumors, and radiation-resistant cancers. Particle therapy is widely adopted in oncology centers, research institutions, and specialized cancer treatment facilities.
The report comprises the Particle Therapy Market Share, Size & Industry Analysis, based on Type of Particle (Proton Therapy, Carbon Ion Therapy), System Type (Single-room Systems, Multi-room Systems), Cancer Type (Prostate Cancer, Lung Cancer, Brain and Spinal Cord Tumors, Head and Neck Cancer, Breast Cancer, Other Cancers), End-User (Hospitals, Cancer Treatment Centers, Academic and Research Institutes), and Region (North America, Europe, Asia-Pacific, Middle East & Africa, Latin America), and Forecast, 2025–2032.
The report contains detailed information on Particle Therapy Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Segmental Analysis :
Based on type of particle, the market is segmented into Proton Therapy and Carbon Ion Therapy.
- Proton Therapy accounted for the largest market share in 2024, driven by its precision in targeting cancer cells while sparing healthy tissues. It is widely used for treating prostate, lung, and pediatric cancers due to its safety and effectiveness.
- Carbon Ion Therapy is projected to grow at the fastest CAGR due to its superior ability to treat radio-resistant and aggressive tumors, providing higher biological effectiveness than proton therapy.
Based on system type, the market is segmented into Single-room Systems and Multi-room Systems.
- Multi-room Systems led the market in 2024 due to their ability to treat multiple patients simultaneously, enhancing operational efficiency in large hospitals and cancer treatment centers.
- Single-room Systems are expected to grow rapidly, fueled by lower installation costs and increased accessibility for smaller clinics and research facilities.
Based on cancer type, the market is segmented into Prostate Cancer, Lung Cancer, Brain and Spinal Cord Tumors, Head and Neck Cancer, Breast Cancer, and Other Cancers.
- Prostate Cancer held the largest market share in 2024, driven by the increasing incidence of prostate cancer and the effectiveness of particle therapy in minimizing side effects.
- Brain and Spinal Cord Tumors are anticipated to grow at the fastest CAGR, supported by the need for highly precise treatments to avoid damage to critical brain structures.
Based on end-user, the market is segmented into Hospitals, Cancer Treatment Centers, and Academic and Research Institutes.
- Cancer Treatment Centers dominated the market in 2024, accounting for 51.50% of the market share, due to their focus on advanced technologies and specialized care for complex cancer cases.
- Academic and Research Institutes are projected to grow at the fastest rate, driven by increased research funding and advancements in clinical trials for particle therapy.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America held the largest market share in 2024, valued at USD 318.62 million, driven by leading healthcare institutions, advanced medical technologies, and government support for cancer treatment.
- Asia-Pacific is expected to register the fastest CAGR of 7.0%, fueled by growing healthcare infrastructure investments in Japan, China, and South Korea and increasing access to advanced cancer treatments.
| Report Attributes | Report Details |
| Study Timeline | 2019-2032 |
| Market Size in 2032 | USD 1,601.60 Million |
| CAGR (2025-2032) | 6.6% |
| Type of Particle | Proton Therapy, Carbon Ion Therapy |
| System Type | Single-room Systems, Multi-room Systems |
| Cancer Type | Prostate Cancer, Lung Cancer, Brain and Spinal Cord Tumors, Head and Neck Cancer, Breast Cancer, Other Cancers |
| End-User | Hospitals, Cancer Treatment Centers, Academic and Research Institutes |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Particle Therapy Industry:
- Varian Medical Systems (United States)
- Siemens Healthineers (Germany)
- Hitachi Ltd. (Japan)
- Mevion Medical Systems (United States)
- ProNova Solutions (United States)
- Sumitomo Heavy Industries, Ltd. (Japan)
- RaySearch Laboratories AB (Sweden)
- Ion Beam Applications S.A. (IBA) (Belgium)
- Accuray Incorporated (United States)
- Elekta AB (Sweden)
Recent Industry Developments :
- April 2024: Varian Medical Systems introduced a next-generation proton therapy system with enhanced imaging capabilities for precise tumor targeting.
- June 2023: Hitachi Ltd. partnered with a leading cancer institute in Japan to expand carbon ion therapy capabilities.
- August 2023: Ion Beam Applications (IBA) launched a compact single-room proton therapy system aimed at making advanced cancer treatments more accessible.
